2020年泰国儿童和青少年腮腺炎血清流行病学调查
泰国自1997年引入单剂含腮腺炎疫苗、2010年引入两剂。本研究对145名3-9岁儿童和422名10-18岁青少年进行横断面调查,采用EUROIMMUN ELISA法检测腮腺炎IgG,以≥22 RU/mL为血清阳性。儿童血清阳性率82.1%(95%CI 74.8-87.9),青少年41.7%(95%CI 37.0-46.6)。接种2剂且末次接种≥5年后仅51.3%维持IgG≥22 RU/mL,IgG滴度与第二剂接种间隔呈负相关(R=-0.44,p<0.001)。作者认为年轻成人可能需要MMR疫苗加强剂。
要点
- 儿童腮腺炎血清阳性率82.1%(95%CI 74.8-87.9),高于青少年的41.7%(95%CI 37.0-46.6)。
- 接种2剂且末次接种≥5年后,仅51.3%维持IgG≥22 RU/mL。
- 腮腺炎IgG滴度与第二剂接种时间间隔呈负相关(R=-0.44,p<0.001)。
核心结论
- 儿童腮腺炎血清阳性率高于青少年,接种2剂疫苗≥5年后抗体维持率下降,作者认为年轻成人可能需要MMR疫苗加强剂。
研究设计与样本
- 横断面研究,纳入145名3-9岁儿童和422名10-18岁青少年,采用EUROIMMUN ELISA法检测腮腺炎IgG,以≥22 RU/mL为血清阳性。
主要发现
- 儿童腮腺炎血清阳性率为82.1%(95%CI 74.8-87.9),青少年为41.7%(95%CI 37.0-46.6)。
- 接种2剂腮腺炎疫苗且末次接种≥5年后,仅51.3%维持IgG≥22 RU/mL。
- 腮腺炎IgG滴度与第二剂疫苗接种时间间隔呈负相关(R=-0.44,p<0.001)。
临床怎么用
- 作者认为年轻成人可能需要MMR疫苗加强剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thailand has implemented single-dose mumps-containing vaccines since 1997 and two doses since 2010. This study aimed to describe the seroprevalence of mumps among children who received one- or two-dose mumps vaccines. A cross-sectional study of 145 children (aged 3-9 years) and 422 adolescents (10-18 years) was conducted. Mumps IgG seropositivity was defined as ≥ 22 RU/mL by EUROIMMUN ELISA method. The mumps seroprevalence was higher in children (82.1%, 95% CI 74.8-87.9) compared to adolescents (41.7%, 95% CI 37.0-46.6) who had received at least one dose of the mumps vaccine. Among those receiving 2 doses of mumps vaccine at ≥ 5 years after their last mumps vaccination, only 51.3% had maintained IgG ≥ 22 RU/ml. There was a reverse correlation between mumps IgG titer and the time interval from the second dose of mumps vaccine (R = -0.44, p < 0.001). A booster dose of MMR vaccine in young adults may be needed.
引用
- Anugulruengkitt S, Angsuwatcharakon P, Puthanakit T, et al. Seroprevalence of mumps among children and adolescents in Thailand, 2020. Vaccine. 2022. PMID: 35078667. doi:10.1016/j.vaccine.2022.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。